BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy. The FDA has granted fast track designation to BGB-16673 for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received 2 or more prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.1.

FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL

SurvivorNet

When it comes to treating non-Hodgkin lymphoma, bispecific antibodies are a unique targeted therapy that essentially attack cancer on two fronts — and recent approvals mean more patients have access.

Bispecific Antibodies for Lymphoma: What Does the Future Look Like for the Promising Targeted Therapy?

The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma. The FDA has granted an orphan drug designation to opaganib (Yeliva, ABC294640) for the treatment of patients with neuroblastoma. Neuroblastoma develops from immature nerve cells and makes up 15% of all...

FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia. Jeff Sharman, MD, medical director of hematology research at US Oncology, discusses findings from the ELEVATE-TN trial (NCT02475681) of acalabrutinib (Calquence) with or without obinutuzumab...

Sharman Discusses ELEVATE-TN Trial Findings in CLL

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma. The Food and Drug Administration (FDA) will fast track, BGB-16673 for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has previously been treated with two or more prior therapies, according to BeiGene, the manufacturer of the novel drug.

FDA Fast Tracks BGB-16673 for CLL, SLL

Federal drug safety regulators have received nearly 300,000 adverse event reports involving health problems with Ozempic, Wegovy, Mounjaro and similar drugs from the same class of medications, highlighting the growing concerns about side effects associated with the widely used diabetes and weight loss treatments. In a report published last week...

FDA Database Reveals High Number of Severe Adverse Events Involving Problem from Ozempic, Similar GLP1 Drugs

The MACI Arthro can be administered through small incisions using custom instruments to repair cartilage defects in the knee. The FDA has approved Vericel Corporation’s MACI for repairing cartilage defects in the knee. According to the company, MACI uses a patient’s own cells cultured on a porcine collagen membrane. This method, also known as MACI Arthro, can be administered through small incisions using custom instruments, providing a substantial improvement in full-thickness cartilage defects up to 4 cm² in size, offering a less invasive option, according to the company.1.

FDA Approves Arthroscopic Delivery of Vericel’s MACI for Knee Cartilage Defects

People are excited to use semaglutide, a diabetes drug popular for assisting weight loss that's commonly sold as Ozempic and Wegovy — and there's good reason to be. But the Food and Drug Administration is now warning the public not to get carried away, issuing an alert that it's received reports of people getting hospitalized after overdosing on the drug, in some cases taking up to 20 times the recommended dosage.

FDA Says People Are Taking 20 Times the Proper Dose of Ozempic and Overdosing

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

NewsNinja

An Aldi shopper recently shared her disturbing experience with a moldy rice package from the supermarket, sparking debate. A TikTok user named @defonotlils posted a video on June 6 that quickly became popular, accumulating more than 674,600 views. In the video, she shares what happened after finding out about something.

This is why I don’t shop at Aldi: Woman can’t believe what she found in her packaged rice from Aldi

Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, has initiated its Phase 2a trial for PP405, a topical small molecule designed to treat androgenetic alopecia. The study will evaluate safety and efficacy in 60 diverse participants, including both women and men. The company has secured $14 million in Series A-1 financing, led by GV, following positive Phase 1 results. This funding will accelerate the clinical program for this innovative hair loss treatment.

Regenerative Hair Loss Treatment Targets Dormant Follicle Stem Cells [Clinical Trial]

A complete blood count, chemistry profile, immunoglobulin test, and light chain assay are among the important blood tests doctors use to help diagnose multiple myeloma. Multiple myeloma is a type of cancer that affects the white blood cells that your bone marrow produces. Doctors can help diagnose multiple myeloma using...

How Do Blood Tests Help in Multiple Myeloma Diagnosis?

Reuters

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge for AstraZeneca's blockbuster drug Tagrisso.

J&J's chemotherapy-free treatment for lung cancer gets US approval

Researchers have offered a comprehensive understanding of the progression of multiple myeloma from a treatable condition to a high-risk disease by providing insights into its genetic diversity and subtypes, according to a recent study published by Skerget et al in Nature Genetics. Background. Multiple myeloma is the second most common...

Novel Insights Into Multiple Myeloma Progression

Ozempic and Wegovy may have some new competition. Eli Lilly has announced that its new diabetes drug, Zepbound (tirzepatide), reduced the risk of developing Type 2 diabetes by 94% in prediabetic adults in a clinical trial. Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment period, with...

Eli Lilly says its new diabetes drug was 94% effective in clinical trials

Doctors often consider a combination of medications to treat multiple myeloma, including chemotherapy, various immunotherapies, and other supportive drugs to help with complications like bone disease. Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow. Treating multiple myeloma often requires different types of medications...

A Comprehensive List of Multiple Myeloma Medications

Marouf Alhalabi ORCID: orcid.org/0000-0001-5027-20961 & Soumar Mueen Alziadan ORCID: orcid.org/0009-0000-3099-99331. Virology Journal volume 21, Article number: 188 (2024) Cite this article. Metrics details. Abstract. Background. The role of cytomegalovirus infection as an opportunistic pathogen in exacerbating ulcerative colitis and its response to treatment remain a topic of ongoing debate. Clinicians...

A diagnostic dilemma: cytomegalovirus colitis as an uncommon comorbidity in inflammatory bowel disease: a case report

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration. Case: Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept. Clinical Presentation:. 70-year-old man diagnosed 6 months ago with LR-MDS with multilineage dysplasia - moderate anemia (Hb 11.2) and thrombocytosis...

Clinical Benefit of Luspatercept Dose Titration: Real-World Evidence

Georgia State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Appling County, GA

Daily Coffee Press

A 40-year-old man from Appling County, Christopher Eric Stone, with a significant criminal history, was recently sentenced to over five years in prison after pleading guilty to possession of methamphetamine with intent to distribute, according to officials from the Department of Justice.

Georgia Man Sentenced to Over 5 Years for in Federal Prison for Meth Distribution

According to officials with the Southern District of Georgia, two recently unsealed federal indictments have charged 23 defendants in a series of broad conspiracies involving the use of drones to smuggle methamphetamine, marijuana, and cell phones into state prisons in Georgia.

23 Defendants Charged in Federal Indictments for Drone-Smuggling Drug Operation in Georgia

Habte Yimer, MD, discussed the findings from the phase 3 ALPINE trial and explored how these results are shaping clinical decisions in chronic lymphocytic leukemia treatment. The development of Bruton tyrosine kinase (BTK) inhibitors has transformed the treatment landscape for patients with chronic lymphocytic leukemia (CLL). However, oncologists often question which is best to use for their patients.

ALPINE Trial Highlights Zanubrutinib's Advantage in CLL

NewsBreak

Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL

BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or...

Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL

Comments / 0